Prof. Dirk Jager

Prof. Dirk Jager

Verified
Chairman
  • Medical Oncologist
Experience
32 yrs
AboutEducationAwardsSimilar doctorsFAQ

About Prof. Dirk Jager

  • Prof. Dirk Jager is a well-known Medical Oncologist with more than 28 years in the field.
  • He is a member of the Cancer Vaccine Collaborative, Cancer Research Institutes, New York, and many such organizations globally.
  • He studied medicine in Lübeck and Freiburg from 1985 to 1991 and later completed his practical year at the Karlsruhe Municipal Hospital.
  • In 1998, he successfully completed his specialist examination for internal medicine and then received a two-year research fellowship at the Cancer Research Institute in New York City. 
  • In 2003, he completed his habilitation in internal medicine at the Mainz University Clinic and received recognition for the specialization in hematology and internal oncology in the same year.
  • He holds expertise in Lymphomas, Bone marrow transplant, Acute Leukemia, Multiple myeloma, Breast Cancer, et al.
  • He has several publications to his credit in various prestigious national and international journals.

Location

  • VerifiedFellowship, Fellowship, Cornell Medical Center(1998)

Papers Published

  1. Tumoral immune cell exploitation in colorectal cancer liver metastases can be targeted effectively by anti-CCR5 therapy in cancer patients. Halama N, Zoernig I, Berthel A, Kahlert C, Klupp F, Suarez-Carmona M, Suetterlin T, Brand K, Krauss J, Lasitschka F, Lerchl T, Luckner-Minden C, Ulrich A, Koch M, Weitz J, Schneider M, Buechler MW, Zitvogel L, Herrmann T, Benner A, Kunz C, Luecke S, Springfeld C, Grabe N, Falk CS, Jäger D. Cancer Cell 2016, 29(4):587-601.
+ Read More
  1. Prognostic Significance of Spontaneous Antibody Responses against Tumor-Associated Antigens in Malignant Melanoma Patients. Zörnig I, Halama N, Lorenzo Bermejo J, Ziegelmeier C, Dickes E, Migdoll A, Kaiser I, Waterboer T, Pawlita M, Grabe N, Ugurel S, Schadendorf D, Falk CS, Eichmueller SB, Jäger D. Int J Cancer 2015, 136:138-51.
  2. Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25. Hannani D, Vétizou M, Enot D, Rusakiewicz S, Chaput N, Klatzmann D, Desbois M, Jacquelot N, Vimond N, Chouaib S, Mateus C, Allison JP, Ribas A, Wolchok JD, Yuan J, Wong P, Postow M, Mackiewicz A, Mackiewicz J, Schadendorff D, Jaeger D, Zörnig I, Hassel J, Korman AJ, Bahjat K, Maio M, Calabro L, Teng MW, Smyth MJ, Eggermont A, Robert C, Kroemer G, Zitvogel L. Cell Res.  2015, 25(2):208-24.
  3. Overcoming drug-resistant herpes simplex virus (HSV) infection by a humanized antibody. Krawczyk A, Arndt MA, Grosse-Hovest L, Weichert W, Giebel B, Dittmer U, Hengel H, Jäger D,  Schneweis KE, Eis-Hübinger AM, Roggendorf M, Krauss J.  Proc Natl Acad Sci USA 2013, 110(17):6760-5.
  4. Low-dose irradiation programs macrophage differentiation to an iNOS⁺/M1 phenotype that orchestrates effective T cell immunotherapy. Klug F, Prakash H, Huber PE, Seibel T, Bender N, Halama N, Pfirschke C, Voss RH, Timke C, Umansky L, Klapproth K, Schäkel K, Garbi N, Jäger D, Weitz J, Schmitz-Winnenthal H, Hämmerling GJ, Beckhove P. Cancer Cell 2013, 24(5):589-602.

Send Your Enquiry

Fill in your details and our medical experts will contact you within 24 hours.

By submitting I agree to the Terms of Use and Privacy Policy of Vaidam Health.

Want to consult the doctor?

Don't Ignore Your Health!

Other Top Medical Oncologist In Heidelberg

Dr. Stefan Schonland

Dr. Stefan Schonland

Medical Oncologist
University Hospital Heidelberg · Heidelberg
28+ years of experience
Chat IconChat

FAQ's About Prof. Dirk Jager

Where does Prof. Dirk Jager practice?

Prof. Dirk Jager practices at University Hospital Heidelberg

What is the specialty of Prof. Dirk Jager?

Prof. Dirk Jager specialty is Medical Oncologist

What is the experience of Prof. Dirk Jager?

Prof. Dirk Jager is Medical Oncologist with 32 years of experience.

Our Network

500+

Top Hospitals

10,000+

Doctors

50+

Cities

10+

Countries

Need Assistance?Chat